Form 4: Voyager CSO Sells Shares for Tax Obligations

Voyager Therapeutics' Chief Scientific Officer, Todd Alfred Carter, sold 4,174 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, Inc. (VYGR), reported a sale of common stock.
• The transaction involved the disposition of 4,174 shares of common stock on February 24, 2026.
• The shares were sold at a weighted average price of $3.76 per share, with prices ranging from $3.61 to $3.86.
• This sale was a non-discretionary 'sell-to-cover' transaction, executed pursuant to a durable automatic sale instruction adopted on May 12, 2025.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 21, 2026.
• Following this transaction, Todd Alfred Carter beneficially owns 145,718 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax purposes related to RSU vesting, not a reflection of management's sentiment on the stock.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions, where executives sell shares to satisfy tax obligations upon the vesting of restricted stock units, are a common and routine practice in executive compensation. These sales are typically non-discretionary and are generally not indicative of a change in management's outlook on the company's future prospects or a lack of confidence in the stock, distinguishing them from open market discretionary sales.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• The impact on shareholders is minimal, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the company's fundamentals or management's confidence.

Next Steps

• NA

Key Dates

Recommendation

The transaction is a routine, non-discretionary 'sell-to-cover' for tax obligations related to restricted stock unit vesting. It does not reflect a change in the insider's investment sentiment or the company's fundamentals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Voyager Therapeutics, VYGR, Insider Transaction, Form 4, Stock Sale, Chief Scientific Officer, Todd Alfred Carter, Restricted Stock Units, Tax Withholding